Does Semaglutide Cause Thyroid Cancer? What the Research Actually Shows

If you are researching semaglutide for weight management, you have probably come across warnings about thyroid cancer. The FDA requires all semaglutide medications to carry a boxed warning about thyroid C-cell tumors. That kind of language can be alarming, especially when you are trying to make a careful decision about your health.

This article breaks down what the actual evidence shows: why the warning exists, what animal studies found, what human clinical data says, and what this means for you as someone considering or currently using semaglutide.

> Important disclaimer: Compounded semaglutide is not FDA-approved. This article is for educational purposes only and does not constitute medical advice. Please discuss your individual risk factors with your prescribing provider before starting or stopping any medication.

---

Where Does the Thyroid Warning Come From?

The FDA's boxed warning on semaglutide-based medications states that thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), have been observed in rodent studies. It goes on to say that the relevance of these findings to humans is not yet established.

This warning was not triggered by cases of thyroid cancer in humans. It came from preclinical animal studies conducted during the drug development process.

In those rodent studies, long-term exposure to GLP-1 receptor agonists at high doses caused C-cell tumors in the thyroids of rats and mice. These tumors involve calcitonin-producing cells in the thyroid, not the more common type of thyroid cancer (papillary or follicular thyroid cancer).

---

Why Rodent Findings Do Not Directly Translate to Humans

This is the part that matters most for context. Rodents are not reliable predictors of GLP-1-related thyroid risk in humans, and the scientific community has been clear about why.

In rodent thyroid tissue, GLP-1 receptors are expressed at significantly higher concentrations than in human thyroid tissue. This difference in receptor density is the key mechanistic distinction. When semaglutide binds to these receptors in rodents, it triggers cellular changes in the thyroid that have not been observed to the same degree in humans.

Research published in the Journal of Clinical Investigation, which reviewed the adverse effect profile of GLP-1 receptor agonists across metabolic and obesity indications, notes that the biological basis for extrapolating rodent C-cell findings to human thyroid risk is weak because of fundamental differences in GLP-1 receptor expression between species [4].

The FDA was aware of this when approving semaglutide. The boxed warning is a precautionary measure reflecting the animal data, not a conclusion that human thyroid cancer risk is elevated.

---

What Human Clinical Trial Data Shows

Semaglutide has been studied in large, rigorous clinical trials involving tens of thousands of participants over multi-year periods. These trials tracked thyroid cancer events as part of their safety monitoring.

The STEP 1 trial, published in the New England Journal of Medicine, evaluated semaglutide 2.4 mg weekly in 1,961 adults with obesity over 68 weeks. The researchers monitored for serious adverse events including thyroid cancer [1]. No clinically meaningful elevation in thyroid cancer was detected.

Across the STEP trial program and other semaglutide trials, thyroid cancer rates in treated participants were not statistically different from those in placebo groups. A comprehensive review of GLP-1 receptor agonists and cancer outcomes, published in Nature Reviews Clinical Oncology, assessed the full body of evidence and found that the thyroid cancer signal in humans remains uncertain at best, and that current trial data does not support a clear causal link [3].

---

The French Observational Study: What It Found and What It Cannot Prove

In 2023, a study published in Diabetes Care examined French national health records and found that patients treated with GLP-1 receptor agonists had a higher rate of thyroid cancer diagnoses compared to those treated with other diabetes medications, specifically sulfonylureas [see ref 36356111].

This observational study was widely reported and alarmed many patients. But it has important limitations that are critical to understand.

Observational studies track what happens in real-world populations. They cannot establish cause and effect. The population taking GLP-1 medications may differ from the comparison group in ways that affect cancer risk, including differences in body weight, surveillance intensity, age, comorbidities, and how long patients were followed.

Multiple research teams published critiques of the methodology in the same issue of Diabetes Care. The Bezin team responded and acknowledged the study's limitations. A subsequent comprehensive assessment of thyroid cancer risk associated with GLP-1 receptor agonist use, published in Diabetes, Obesity and Metabolism in 2026, concluded that the current evidence is insufficient to conclude that GLP-1 receptor agonists increase thyroid cancer risk in humans, while calling for continued pharmacovigilance [2].

The scientific conversation about this question is ongoing. The evidence does not currently support the conclusion that semaglutide causes thyroid cancer in humans, but researchers continue to study this carefully.

---

Who Should Be Most Cautious

There are specific groups of people for whom thyroid concerns are more clinically relevant, and who should have a detailed conversation with their provider before starting semaglutide.

Personal or family history of medullary thyroid carcinoma (MTC). Semaglutide is contraindicated in people with a personal or family history of MTC. This is not based on observational data. It is a direct precautionary application of the animal study findings, applied conservatively to the highest-risk population.

Multiple Endocrine Neoplasia type 2 (MEN2). MEN2 is a genetic condition associated with elevated MTC risk. Semaglutide is also contraindicated in people with MEN2.

For most other people, including those with common, differentiated thyroid cancers (papillary or follicular), the contraindication does not automatically apply, but a provider-led conversation is essential.

---

Symptoms Worth Knowing

Regardless of the current state of the science on population-level risk, knowing what symptoms to watch for is always a reasonable step. Medullary thyroid carcinoma can present with:

• A lump or mass in the front of the neck
• Hoarseness or a change in voice quality
• Difficulty swallowing
• Persistent neck pain
• Swollen lymph nodes in the neck

These symptoms have many possible causes and are not specific to cancer. But if you notice any of these while on semaglutide, contact your provider promptly. Thyroid cancer is highly treatable when caught early.

Your provider may monitor your calcitonin levels, a marker associated with C-cell activity, as part of ongoing thyroid safety monitoring. This is not universally required but is reasonable to discuss if you have concerns or relevant risk factors.

---

What the FDA Has and Has Not Done

It is worth being clear about the regulatory picture. The FDA:

• Approved semaglutide (Ozempic, Wegovy) with a boxed warning about thyroid C-cell tumors based on animal data
• Has reviewed post-market surveillance data and observational evidence as it has accumulated
• Has not issued a safety alert, required labeling changes, or restricted use based on human thyroid cancer data as of this writing
• Continues to require pharmacovigilance and post-market reporting for this signal

A review covering the full spectrum of GLP-1 receptor agonist adverse effects, published in the Journal of Clinical Investigation, characterizes the current regulatory position as appropriately precautionary given the animal data while not overstating human risk evidence [4].

Regulatory agencies around the world, including the European Medicines Agency (EMA), have similarly maintained approval with precautionary language.

---

Monitoring Your Thyroid Health on Semaglutide

If you are currently using a GLP-1 medication or are planning to, these are reasonable steps to discuss with your provider:

1. Disclose your personal and family history. Let your provider know if you have any history of thyroid disease, MTC, or MEN2 before starting.
2. Report new symptoms promptly. Neck lumps, hoarseness, or swallowing difficulty should be evaluated without delay.
3. Attend regular follow-up appointments. Your prescribing provider monitors your overall health status, including for any unexpected changes.
4. Ask about thyroid-specific monitoring if you have risk factors or significant concerns. Calcitonin measurement can be considered on an individual basis.

You do not need to approach this issue with alarm. Current evidence does not show that semaglutide causes thyroid cancer in the general population. What the science does call for is informed, ongoing attention, which is what a good provider-patient relationship provides.

---

Key Takeaways

• The FDA's thyroid cancer warning on semaglutide is based on rodent studies, not human cases.
• Rodents express GLP-1 receptors in thyroid tissue at much higher levels than humans, limiting how directly these findings apply.
• Large human clinical trials have not shown a statistically meaningful elevation in thyroid cancer rates in people taking semaglutide.
• A 2023 French observational study raised questions, but observational studies cannot prove causation, and multiple experts have noted methodological limitations.
• The most recent evidence reviews conclude that the human thyroid cancer risk from GLP-1 receptor agonists remains uncertain, not established.
• Semaglutide is contraindicated in people with a personal or family history of MTC or MEN2. For others, the discussion belongs with your provider.

---

Starting Your Weight Loss Journey

If you have questions about your individual thyroid risk or whether GLP-1 treatment is appropriate given your medical history, Prescriva connects you with licensed healthcare providers who can evaluate your situation in full and develop a personalized plan.

Ready to explore your options? [Check your eligibility](/quiz)

---

> Disclaimer: This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. Individual risk varies based on personal and family medical history. Prescriva's compounded medications are prescribed by licensed healthcare providers following individual medical evaluation and dispensed by licensed 503A compounding pharmacies. Blue Oak Services LLC dba Prescriva is a Management Services Organization (MSO) that does not practice medicine.

---

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. PMID: 33567185

1. Vilsbøll T, Torekov SS, Hjerpsted JB, et al. Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. *Diabetes Obes Metab.* 2026. PMID: 41287564

1. Mannucci E, Monami M, Candido R, et al. Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown. *Nat Rev Clin Oncol.* 2026. PMID: 41803464

1. Jalleh RJ, Rayner CK, Jones KL, Horowitz M. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. *J Clin Invest.* 2026. PMID: 41697736

1. Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. *Diabetes Care.* 2023;46(2):384-390. PMID: 36356111